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This paper contains a joint ESHG/ASHG position document with recommendations regarding responsible innovation in prenatal
screening with non-invasive prenatal testing (NIPT). By virtue of its greater accuracy and safety with respect to prenatal
screening for common autosomal aneuploidies, NIPT has the potential of helping the practice better achieve its aim of
facilitating autonomous reproductive choices, provided that balanced pretest information and non-directive counseling are
available as part of the screening offer. Depending on the health-care setting, different scenarios for NIPT-based screening for
common autosomal aneuploidies are possible. The trade-offs involved in these scenarios should be assessed in light of the aim
of screening, the balance of beneﬁts and burdens for pregnant women and their partners and considerations of cost-
effectiveness and justice. With improving screening technologies and decreasing costs of sequencing and analysis, it will
become possible in the near future to signiﬁcantly expand the scope of prenatal screening beyond common autosomal
aneuploidies. Commercial providers have already begun expanding their tests to include sex-chromosomal abnormalities and
microdeletions. However, multiple false positives may undermine the main achievement of NIPT in the context of prenatal
screening: the signiﬁcant reduction of the invasive testing rate. This document argues for a cautious expansion of the scope of
prenatal screening to serious congenital and childhood disorders, only following sound validation studies and a comprehensive
evaluation of all relevant aspects. A further core message of this document is that in countries where prenatal screening is
offered as a public health programme, governments and public health authorities should adopt an active role to ensure the
responsible innovation of prenatal screening on the basis of ethical principles. Crucial elements are the quality of the screening
process as a whole (including non-laboratory aspects such as information and counseling), education of professionals, systematic
evaluation of all aspects of prenatal screening, development of better evaluation tools in the light of the aim of the practice,
accountability to all stakeholders including children born from screened pregnancies and persons living with the conditions
targeted in prenatal screening and promotion of equity of access.
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INTRODUCTION
In the past few years, several professional societies have issued position
statements on non-invasive testing (NIPT) for Down syndrome
(trisomy 21) and other common autosomal aneuploidies (trisomy
18 and 13), based on sequencing of cell-free DNA (cfDNA) in
maternal plasma.1–5 The focus of these position statements was on
NIPT as a promising novel approach to fetal aneuploidy screening, the
level of evidence for the clinical validity of NIPT-based testing for
these conditions in different populations, the inherent limitations of
NIPT-based testing for these conditions, the risk of a premature
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introduction and the need for further research including cost-
effectiveness studies. These earlier statements made the point that
NIPT should not be presented as a diagnostic test for fetal aneuploidy;
many statements also insisted that there is insufﬁcient evidence for
NIPT to be used as a screening test in a general obstetrical population,
although recently there have been several studies that demonstrate
good performance in women at average risk (see below). Several
specialty expert groups have also issued documents addressing speciﬁc
concerns or points of attention, such as counseling issues arising with
NIPT,6 or the impact of NIPT on prenatal ultrasound practice.7
This document discusses the emerging and future scenarios for
NIPT-based prenatal screening from an ethical perspective. Ethical
aspects have been discussed in the literature,8–12 in reports by National
Ethics Committees and other public health bodies or institutions,13–15
but have not yet been the main focus of professional position
statements. This document is the result of a unique collaboration
between the Public and Professional Policy Committee of the
European Society of Human Genetics (ESHG) and the Social Issues
Committee of the American Society of Human Genetics (ASHG). The
ﬁrst draft was written by the ﬁrst author and discussed by members of
both committees and external experts. After adaptation, the text was
emailed and posted on the ESHG website for membership consultation
on 10 October 2014 inviting comments til 15 November 2014, and
sent to the ASHG and ESHG Boards to elicit further comments. The
ﬁnal version was approved by the ESHG Board on 15 December 2014
and by the ASHG Board on 23 December 2014, and also endorsed by
the Human Genetics Society of Australasia, the Australasian Association
of Clinical Geneticists, the British Society for Genetic Medicine, the
Czech Medical Genetics Society and the PHG Foundation
(Cambridge, UK).
In this document, we use ‘NIPT’ as a general term for non-invasive
prenatal testing based on quantitative or qualitative analysis of cfDNA
in maternal blood, used in the context of prenatal screening. By
prenatal screening we understand the routine offer of medical tests to
pregnant women without a known individual higher risk of having a
child with a speciﬁc disorder or a compromised outcome of the
pregnancy. This is usually a two-tier procedure, consisting of a
screening test stricto sensu with diagnostic follow-up testing in case
of a positive result. In many Western countries, prenatal screening is
offered in a public health setting. This entails a systematic approach
with quality controlled uniform provision procedures, and (different
levels of) public funding. In other countries or states, such as in the
USA, prenatal screening is made available to (self-paying or insured)
patients through individual practitioners or practices, ideally in
accordance with professional guidelines. Finally, NIPT for sex
selection and paternity testing is commercially offered by laboratories
as direct-to-consumer (DTC) tests.
When, in this document, we refer to ‘women and their partners’, or
‘women or couples’, this is to acknowledge that decisions about
prenatal screening or its outcomes will often be shared by pregnant
women with their partners and that these partners (mostly the
biological father-to-be) do have an interest in knowing a diagnosis
in their future child. Moreover, depending on the conditions tested,
some outcomes may also have implications for the father himself.16
However, professionals should ascertain that consent for prenatal
testing and other procedures is based on a free and voluntary decision
of the woman herself, as it is her body and her pregnancy. Legally,
prenatal screening is offered to the woman only, with her partner
having no say in the relevant decisions.
BACKGROUND
After the presence of cell-free fetal DNA in maternal blood
was described in 1997,17 early applications of NIPT included the
determination of Rhesus D blood-group status and fetal sex as well as
the diagnosis of autosomal dominant disorders of paternal
inheritance.18,19 The use of NIPT to screen for the presence of fetal
aneuploidy became feasible with the development of massive parallel
sequencing (MPS) and counting of cfDNA fragments.20,21 Most
current tests for this purpose use whole genome MPS in order to
quantitatively compare the amount of, for example, chromosome 21
DNA molecules in a maternal sample with that of an euploid reference
sample. Other tests use targeted sequencing, mapping only the
chromosome regions of interest, or use a qualitative SNP-based
approach.22
NIPT for common autosomal aneuploidies: test performance
In a recent meta-analysis in which the results of a large number of
studies were pooled, NIPT was found to have a sensitivity of 99% for
trisomy 21, and a speciﬁcity of 99.92%.23 For trisomy 18, the reported
ﬁgures were 96.8% (sensitivity) and 99.85% (speciﬁcity). For trisomy
13, they were 92.1 and 99.80% respectively.23 It should be noted,
however, that the performance of NIPT is better documented in
trisomies 21 and 18 than for trisomy 13, which is a less frequent
condition.24
Only a few of these studies have been conducted in lower risk
populations. However, there is growing evidence that comparably
good results can also be achieved in general obstetrical populations,
making NIPT an alternative to current ﬁrst-trimester screening
protocols.25–32 In the prospective multicenter Comparison of
Aneuploidy Risk Evaluation (CARE) study (primary analysis cohort
of 1914 cases), Bianchi et al25 compared NIPT as a ﬁrst-tier screening
test with prenatal screening in the many different ways in which it is
being performed in the United States. They found a sensitivity of
100% (for all three trisomies) (95% conﬁdence interval (CI):
99.8–100), at a speciﬁcity of 99.7 and 99.8% for trisomies 21 and
18, respectively. A much larger prospective study, carried out in
centers in the USA, Canada and Europe (the non-invasive examination
of trisomy using cell-free DNA analysis (NEXT) study) is expected to
conﬁrm these observations.30 In this study, NIPT was compared with
a standard ﬁrst-trimester screening in a general risk population of
pregnant women.
A major reason why NIPT for common autosomal aneuploidies is
less than fully accurate is because the DNA sequenced represents a
combination of maternal and fetal cell-free DNA, with the latter
actually deriving from the placenta.33 A positive result (signaling a
suspected aneuploidy) may be generated by factors other than an
aneuploid fetal karyotype, including placental mosaicism, a vanishing
twin or a maternal tumor; false alarms are inevitable.34
The actual impact of this becomes clear if the test is assessed in
terms of its predictive value (rather than only its sensitivity and
speciﬁcity), as this measure also takes the low prevalence of the
relevant conditions in the target population into account. For instance,
the positive predictive value (PPV) for trisomy 21 in the CARE-study
was found to be 45.5% (95% CI: 16.7–76.6), meaning that in a general
risk population more than half of positive NIPT results may generate
false alarms.25 Although 10 times better than the PPV of current ﬁrst-
trimester screening in a similar population (as reported in the same
study), this is still far below the near 100% required for a diagnosis of
trisomy 21.
If NIPT is offered to pregnant women with a higher a priori risk, the
PPV increases. But even for those at a very-high a priori risk of 1:5, the
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PPV does not exceed 99%.35 This is why those who would consider a
termination of pregnancy in case of a fetus with aneuploidy, should
always be counselled to have follow-up testing (preferably amniocent-
esis) to conﬁrm a positive NIPT result. Whereas trisomy 21 is a
relatively frequent condition (1:500), the lower prevalences of trisomy
18 (2.3 in 10 000) and trisomy 13 (1.4 in 10 000)36 will affect the PPV
of NIPT for these conditions if tested in a general population.37 For
any of these conditions, by contrast, the predictive value of a negative
NIPT result increases with lower a priori risks and is very close to
100% in a general risk population. This means that except for women
at a very-high pretest risk of carrying a child with Down syndrome
(or trisomy 18 or 13) a negative NIPT result is highly reliable.35
However, false negatives cannot be excluded. One possible cause is
that triploidies will not be picked up with present NIPT-technology
(a deﬁciency that is expected to be overcome with technological
improvements38). More generally, it is important that women or
couples are made aware that screening for common aneuploidies will
not pick up all chromosome abnormalities.
Cell-free DNA in the blood of pregnant women is for the most part
of maternal origin. Only a small proportion (~10%) derives from the
fetus (more precisely from the placenta). NIPT requires this ‘fetal
fraction’ of cell-free DNA in maternal blood to be above a minimum
level for adequate analysis, for which most laboratories set a limit at,
for example, 4%.39 Although cell-free fetal DNA can be found in
maternal blood as early as 4 weeks of pregnancy, the fraction may not
yet be large enough if testing is done prior to nine or ten weeks. Earlier
testing may therefore lead to an inaccurate or failed result. However,
in later testing, the fetal fraction may still be too low, due to maternal
factors that are in need of further investigation. One clearly established
risk factor for a failed result is a higher maternal body weight due to a
dilution effect and most probably increased adipocyte turnover in
obese women.40,41 Reported failure rates vary considerably between
laboratories, ranging from 0 to 5%.42 After a failed result, NIPT can be
repeated, or alternative testing can be considered, but this adds
additional time to the screening and diagnostic process that may put
pressure on further choices and may impact on whether the woman
could still have a non-surgical termination. More evidence about
failure rates and risk factors for failed NIPT is necessary. There is also
still limited evidence about the performance of NIPT as a test for fetal
aneuploidy in twin or triplet pregnancies.43
ETHICAL FRAMEWORK FOR PRENATAL SCREENING FOR
FETAL ABNORMALITIES
Because of its connection with (selective) abortion, prenatal screening
for fetal abnormalities is a morally sensitive practice. The relevant
normative framework consists of a context-speciﬁc articulation of the
more general set of principles for population screening, as initially
formulated by Wilson and Jungner and further developed in the
past decades.44–46
Aim of prenatal screening for fetal abnormalities
A core component of this framework concerns the precise aim of
prenatal screening for fetal abnormalities such as Down syndrome.
This is especially important when screening is provided as a public
health programme rather than made available on the initiative of
individual practitioners. Although population screening programmes
are aimed at reducing the morbidity and mortality associated with
disease or disorders in the population, there are two ethical problems
with this aim when prenatal screening is concerned.47 Firstly, if the
success of the programme is thought to depend on the termination
rate of fetuses with abnormalities such as Down syndrome, this may
invite subtle pressure upon women to ask for an abortion if the fetus is
found to be affected. Abortion decisions would thus be turned into
a public health instrument. Secondly, the aim makes the practice
vulnerable to what is known as the ‘disability rights’ or ‘expressivist
critique’, according to which prenatal screening sends a discriminatory
message about the worth of the lives of people living with the relevant
conditions.48 In order to avoid these ethical pitfalls, relevant policy
documents stress that prenatal screening for fetal abnormalities is
aimed, not at preventing the birth of children with speciﬁc abnorm-
alities, but at enabling autonomous reproductive choices by pregnant
women and their partners.13,49–51 This may need to be qualiﬁed as
referring to meaningful choices related to serious health problems,
as maximizing reproductive autonomy as such cannot possibly be
a justiﬁed public health aim.49,52
This account of the aim of the practice (and thus of its ‘clinical
utility’) should be reﬂected in how prenatal screening for fetal
abnormalities is presented, offered, carried out and evaluated.47
Ideally, the ‘effectiveness’ of the practice should be assessed in terms
of a measure of informed choice rather than only in terms of technical
performance results such as the detection–miscarriage ratio. On the
basis of earlier work, these instruments still need to be further
developed and validated,53,54 together with systematic interventions
(information and counseling approaches) aimed at helping health-care
professionals to facilitate informed choices in prenatal screening.55
Balance of beneﬁts and harms
A further general requirement is that screening practices must be
proportional. This is primarily a matter of the balance of beneﬁts and
harms for those being tested.44–46 In the context of prenatal screening
for fetal abnormalities, the possible beneﬁts for pregnant women or
couples are twofold: reassurance if shown to be at a low risk, or being
helped to make an informed reproductive decision, more speciﬁcally
with regard to continuing (and prepare for the birth of a child with
special needs) or terminating the pregnancy, if the fetus is diagnosed
with a fetal abnormality. Potential harms of prenatal screening include
a false reassurance, decision stress, anxiety especially as a result of
false-positive outcomes, and the risk of losing the pregnancy as
a complication of invasive follow-up testing. As the balance of beneﬁts
and harms is directly affected by aspects such as the accuracy of the
tests, access to follow-up, the quality of laboratory procedures,
balanced information and counseling and so on, these quality aspects
should all be taken into account when evaluating prenatal screening
practices or considering adaptations to existing practices or novel
forms of screening.
Societal and justice aspects
The above elements of the normative framework (aim, balance of
beneﬁts and harms for those tested) also apply when prenatal
screening takes the form of a (commercial) testing offer made available
to patients through individual practitioners or practices.46 However,
when screening is offered as a public health programme, societal and
justice aspects need to be taken into account. This includes possible
consequences for other individuals and groups (including those living
with the relevant conditions), as well as cost-effectiveness of
publicly funded services. As health budgets are inevitably limited
(and increasingly under strain), opportunity costs will have to be taken
into account as well.
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NIPT FOR COMMON AUTOSOMAL ANEUPLOIDIES: CHANGING
THE FIELD
The introduction of NIPT is currently changing the way in which
prenatal screening for Down syndrome (and other common auto-
somal aneuploidies) is offered to pregnant women. In several
countries, individual practices have started offering commercially
available NIPT as a further option next to the existing prenatal
screening tests, initially only to women at a known higher risk (as an
alternative for direct access to invasive testing), but more recently as an
alternative for ﬁrst-tier screening to women at a low or general risk,
even though professional societies do not yet recommend the latter
approach. The availability of NIPT is already leading to a considerable
reduction of invasive procedures in the USA, both as a result of
women choosing NIPT over direct access to invasive procedures and
of the lower false positive rate of NIPT as compared with other ﬁrst-
tier tests.56
In countries with a formal prenatal screening programme, the
approach used in the past consists of a two-tiered procedure starting
with a risk-assessment screen (combined ﬁrst-trimester screening:
cFTS), to be followed, in case of a positive result, by an offer of
invasive testing (amniocentesis, chorion villus sampling; CVS) to allow
a ﬁnal diagnosis through cytogenetic (karyotyping) or molecular
analysis (rapid aneuploidy test, chromosomal microarray). cFTS is
based on two biochemical markers in maternal blood (PAPP-A and
free β-hCG), combined with an ultrasound measuring fetal nuchal
translucency thickness (NT-measurement). A cut-off (typically set at
1:150 or 1:200) is used to determine what outcomes count as positive.
Depending on the maternal age distribution and choice of cut-off,
cFTS has a sensitivity of 85–90% and a speciﬁcity of ~ 95% for trisomy
21. Both methods used for invasive follow-up testing (amniocentesis
and CVS) have a procedure-related miscarriage risk of an estimated
0.5–1%.57 With the low PPV of cFTS-based screening (~5%), an
important drawback of the current approach is that the overwhelming
majority of women undergoing invasive follow-up and exposing
themselves to the risk of those procedures do so without actually
carrying an affected fetus.
Scenarios of NIPT-based screening for common autosomal
aneuploidies
With the advent of NIPT, different scenarios for improving prenatal
screening for common autosomal aneuploidies emerge, each with its
own pros and cons. The following three represent the main options
for using NIPT in practice.
NIPT as a second test after cFTS using current risk cut-offs. In the past
few years, professional bodies and policy authorities have recom-
mended offering NIPT only to women who belong to a higher risk
group, either based on maternal age or a positive cFTS. This limitation
was motivated by the still pending status of the validity of NIPT-based
screening in a general risk population. Inserting NIPT as a second test
dramatically reduces the need for invasive follow-up testing, thus
making the whole prenatal screening trajectory considerably safer.
Because of the reduced need for costly invasive testing, adding NIPT as
a second test may be cost-neutral or even cost-saving, bringing this
approach within easy reach of publicly (or collectively) funded
screening programmes for fetal aneuploidy.58 A drawback is that with
this approach the detection rate will not improve beyond that of cFTS,
as cases that are initially screen negative will also not be found with the
second screening step. As a result of additional false negatives,
detection will, for a ﬁxed uptake, actually be a bit lower than if all
women who had a positive cFTs underwent invasive testing.
Moreover, for a small percentage of women, the screening will consist
of three steps, which will make the whole trajectory longer and more
burdensome (and depending on the health-care context: more costly)
for them, while possibly also impacting upon the choices available
to them.
NIPT as a replacement for cFTS. With recent publications suggesting
equally good test performance in lower risk populations, the further
scenario of using NIPT instead of cFTS will be increasingly considered.
As compared with the previous scenario, this approach would have the
advantage of detecting more pregnancies with aneuploidy and
practically eliminating false reassurance.59 Secondly, using NIPT as a
ﬁrst-tier test signiﬁcantly reduces the number of women who will
receive an initial false alarm. Moreover, since NIPT can be done earlier
in pregnancy than cFTS (at 9–10 weeks), this approach also means
that for those receiving a negative result, testing can be completed
earlier. Should NIPT be introduced as a ﬁrst-tier test, it has been
suggested as a further beneﬁt that pretest information can be more
straightforward as conceptually NIPT would be a more easy to
understand type of test.60 On the other hand, because of the lower
a priori risk in the general population, the PPV of a positive NIPT
result is signiﬁcantly lower in this scenario than with NIPT as a second
test, which will lead to more invasive procedures. As a further
drawback, it has been pointed out that with falling use of cFTS, any
extra information that this test may yield about clinically relevant
conditions other than the targeted aneuploidies (see below) would also
be lost.61,62 Finally, as long as NIPT is still signiﬁcantly more expensive
than cFTS, costs are an important barrier to introducing NIPT as a
ﬁrst test in publicly (or collectively) funded screening programmes for
fetal aneuploidy. Only with a considerable reduction in the costs of
NIPT may this approach become sufﬁciently cost-effective.63,64
NIPT as a second test after adapted cFTS. Using NIPT as a second test
while lowering the cFTS cut-off can be a way to keep costs down while
still improving the detection rate in addition to reducing the need for
invasive follow-up testing (Chitty et al, 2012). With a cut-off of 1:1000,
this approach will now be evaluated in the UK, looking at implications
for prenatal screening under the NHS.62 Above this cut-off, women
will be offered NIPT as a second test, while those with a risk above the
old UK cut-off of 1:150 will be given the choice between NIPT and
direct access to invasive testing. By adding further markers to the cFTS
step, the researchers hope to be able to further enhance the detection
of aneuploidies in this ‘contingent’ model.61,62 The study will
incorporate a health economic evaluation aimed at determining the
budget impact of the proposed approach in comparison to the current
screening pathway, while allowing adaptations.
Uptake
An unknown variable is the uptake of NIPT-based prenatal screening.
This is especially important when prenatal screening is fully funded
from public money, as uptake affects the projected overall costs of
such programmes. At present, uptake of the screening offer varies
greatly in different countries with public health-based prenatal screen-
ing programmes (from ~30 to more than 80%).65 The way in which
screening is embedded in health care (eg offered by midwives or
gynaecologists), including different funding regimes, may have a role,
together with information and counseling practices and professional
attitudes towards prenatal screening.65 Given that women’s perception
of the poor quality of cFTS-based screening in terms of accuracy and
safety (given high chances of being offered invasive follow-up) seems
an important reason why part of the target group at present declines
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the test offer, making prenatal screening more robust in these respects
may lead to render it a more acceptable proposition for more
women66,67 It is also possible that some women who would not
consider abortion of an affected fetus may ﬁnd a positive NIPT-result
sufﬁciently informative even without conﬁrmatory testing in that it
enables emotional preparation for the possible birth of a child with
extra needs. This can be considered a moral gain as it would mean
that, compared with cFTS-based screening, more women can be
helped to make what for them would be a meaningful reproductive
decision.15
Balancing beneﬁts and harms in different scenarios
If NIPT is implemented as a second-tier test, the beneﬁts to harms
ratio of prenatal screening for common autosomal aneuploidies will
considerably improve with the greatly reduced invasive testing rate, as
compared with the current cFTS-based approach. Also in studies
among pregnant women as potential users of NIPT this was seen as an
important beneﬁt.67 Assuming that any remaining uncertainties about
the value of NIPT in a general pregnant population will be removed,
the further debate is about how additional improvements can best be
achieved by moving this better test either partly or completely toward
the front of the screening trajectory. The trade-offs involved may lead
to different choices in different settings and will require further
analysis and stakeholder-research.
For instance, in different scenarios with NIPT as a second-tier test,
the proposal to lower the cut-off in order to allow more women to
proﬁt from NIPT’s higher detection rate, will inevitably lead to a
somewhat higher chance of losing a healthy pregnancy and also to
burdening many more women with a false-positive initial result,
turning them for some amount of time into ‘candidates for invasive
testing’.68 It is important to note that individual women may weigh
these aspects differently, and that even if most would agree with the
choices made by the experts on the basis of a careful balancing of
different perspectives, not all will.68 Also in light of the aim of prenatal
screening for fetal abnormalities (see above), the question arises to
what extent individual women or couples can and should be allowed
to make their own choices with regard to some of those trade-offs.
Clearly, the scope for this will be more limited in the context of a
publicly funded screening programme, where costs are a constraining
factor, than in settings where women or couples have to fully pay
themselves.
Concerns about ‘routinisation’
Concerns have been raised that, precisely as a result of NIPT’s better
performance, it may paradoxically become more difﬁcult to achieve
the aim of enabling autonomous reproductive choices.10,11,14,66,69
These concerns were ﬁrst formulated prior to the actual development
of NIPT, on the assumption that the technology would be accurate
enough to enable the traditional two-step screening for Down
syndrome to be replaced by one simple non-invasive test. It was
feared that this would lead to prenatal screening being presented by
professionals and regarded by pregnant women as a routine procedure,
rather than an option that well-informed women may either accept or
decline. However, the screening would still have the same conse-
quences in case of a positive ﬁnal diagnosis. Preparing women for this
would require giving all relevant information to all of them already at
the pre-screening stage, whereas the present two-step approach
(ideally) allows for further moments of (additional) information and
reﬂection for those with a positive initial screen11,70 By removing the
risk to pregnancy, one-step screening might also deprive women of a
possible reason for declining the screening offer.10,68
Although in any presently realistic scenario, the introduction of
NIPT will not lead to abandoning two-step screening, these concerns
about ‘routinization of prenatal testing’71 should nevertheless be taken
seriously. They are also raised by pregnant women asked to reﬂect on
the pros and cons of introducing NIPT for those conditions.66,67 The
much lower invasive testing rate and related a greater safety of NIPT-
based prenatal screening for common autosomal aneuploidies (in any
of the above scenarios) may lead to normalizing prenatal screening as
just one further test pregnant women are expected to take. As almost
all results will be reassuring, professionals may also ﬁnd it less
important to inform women about the choices they may be faced
with down the line of a further screening trajectory.72 Against the
background of a continuing history of reports pointing at the
discrepancy between the aim of the screening offer and the extent
to which pregnant women are actually making informed choices,73–76
avoiding these routinisation-effects may well be the greatest ethical
challenge of NIPT-based prenatal screening.
Loss of additional ﬁndings with NIPT for common autosomal
aneuploidies
As long as NIPT is used to only look for Down syndrome and
trisomies 18 and 13, introducing this new test will de facto lead to
narrowing the range of clinically relevant conditions that the screening
may bring to light.77 This is because, ﬁrstly, in each of the above
scenarios, the follow-up rate and therefore also the rate of chromo-
somal abnormalities other than the targeted trisomies that may be
detected at follow-up, will be (up to around 20%) lower than with the
traditional approach.77,78 Some of these additional ﬁndings are serious
conditions, not all of which will come to light with the second
trimester fetal anomaly scan.
Although the risk of thus missing a clinically relevant chromosomal
abnormality is actually quite low (estimated range between 1:1600 and
1:4000),59 some commentators have suggested that the beneﬁts of
NIPT may not outweigh the loss of these extra ﬁndings at the stage of
invasive follow-up.78 However, the problem with forgoing those
beneﬁts for this reason is that it puts women at a higher miscarriage
risk in order to maximize the detection of conditions outside the scope
of the screening to which they have consented. There is also an equal
access problem here: maximizing detection of additional ﬁndings at
follow-up does not equally beneﬁt all those initially at the same risk for
the relevant conditions.79 A recent proposal is to make better use of
cFTS markers (including NT-measurement) in order to deﬁne higher
risk groups to whom invasive testing would still have to be offered.77
Clearly, this would require redeﬁning the scope of the screening
(also in the pretest information and consent procedures) as targeting a
wider range of chromosomal abnormalities than Down syndrome and
other common autosomal aneuploidies.
Secondly, in the scenario with NIPT as a ﬁrst-tier test a further loss
of clinically relevant information is to be expected.62,80 This refers to
extra ﬁndings from the ultrasound part of cFTS: cases of a greatly
increased nuchal translucency (NT≥ 3.5 mm) are considered to
require further testing for a range of possible abnormalities including
congenital cardiovascular defects and genetic syndromes such as
Noonan syndrome.81 Additionally, the biochemical markers used in
cFTS may indicate risks of pregnancy complications such as pre-
eclampsia and intra-uterine growth retardation.82 Whether this loss of
information from cFTS should be seen as a (further) reason for not
moving toward using NIPT as a ﬁrst-tier test, is a matter for debate.
An alternative approach is to keep NT-measurement as a separate
screening, for instance as part of a routine ultrasound at 13 weeks.
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With regard to additional screening for risk of pregnancy complica-
tions, there are ethical reasons for keeping this apart (see below).
Additional ﬁndings of NIPT for common autosomal aneuploidies
Depending on targeted or non-targeted analysis and on the level of
resolution, NIPT for common autosomal aneuploidies may lead to
ﬁndings of abnormalities in other chromosomes, including submicro-
scopic abnormalities.83 Ideally, there should be a ﬁt between the range
of abnormalities for which the screening is offered and accepted and
the scope of the test used to ﬁnd those conditions. Women or couples
may otherwise be confronted with outcomes requiring them to make
decisions that they were not sufﬁciently prepared for. These decisions
can be especially difﬁcult when conditions are mild or highly variable
or when health implications are otherwise uncertain. This is not a new
problem: such ﬁndings also emerge at follow-up testing after a positive
cFTS (see previous section). However, at the NIPT stage, they precede
decision making about invasive testing, which may entail putting the
pregnancy at risk for conﬁrming ﬁndings that not only have a low
PPV (because of their low frequency), but that, if conﬁrmed, may still
have highly uncertain implications for the health of the future child.
To the extent that ﬁndings beyond the scope of the screening offer can
reasonably be avoided by technical means, doing so is ethically
preferable. The argument that this would lead to missing ﬁndings
that may be important, should be discussed in terms of whether
broadening the screening offer to include those further ﬁndings would
be justiﬁed or not.
To the extent that additional ﬁndings cannot (reasonably) be
avoided, women or couples should be informed (as part of pretest
information) about the possibility of such ﬁndings and also in general
terms about the range of possible implications that these ﬁndings may
have. As much as reasonably possible, it should also be discussed with
them whether they would or would not want to be informed about
clinically relevant ﬁndings beyond the scope of the screening offer.83
Although there is no such thing as an absolute ‘right not to know’, it
follows from international legal documents such as the European
Convention on Human Rights and Biomedicine that health
professionals involved in the provision of genetic tests should in
principle respect people’s wishes with regard to controlling the
information they may receive as a result of being tested. This holds
a fortiori for prenatal screening, given the above account of the aim of
the practice.
Sex selection for non-medical reasons
A speciﬁc ethical issue related with NIPT is sex selection for non-
medical reasons. Depending on how the test is carried out, the
scenario with NIPT as a ﬁrst screening test will lead to information
about fetal sex being available at an early stage in all screened
pregnancies. Commercial companies offering NIPT currently provide
this information on an optional basis. There is a concern that some
pregnant women and their partners may use this to have an abortion if
the sex of the fetus does not match their preference.
The culturally and socially determined practice of selecting for
males has led to a marked disturbance of the sex ratio in some Asian
countries, with serious social effects.84 Although research has shown
that people in Western countries do not generally have a strong
preference for sons,85 there are reports suggesting sex-selective
abortion for this reason is being practiced in certain cultural
minorities.86
The outcry about the sexist character of this practice has led to
legislation forbidding sex selection for non-medical reasons, which in
most countries is limited to the context of medically assisted
reproduction.87 In 2011, the Parliamentary Assembly of the Council
of Europe has called upon member states to also take legal measures to
counteract sex selection in the context of legal abortion.88 The scope
for this, however, is limited, as the freedom of abortion and the right
of access to information about test results would be at stake. Whereas
in Germany legislation forbids informing pregnant women about the
sex of the fetus in the ﬁrst 12 weeks, the Health Council of the
Netherlands has argued that such measures are disproportionate.15
The best way to counteract improper use of information about fetal
sex is to avoid its generation. As long as NIPT is not also directed at
sex-chromosomal aneuploidies (see below), one could consider ways
to ﬁlter out this information from the test result.
SCOPE OF NIPT-BASED PRENATAL SCREENING
It is expected that in the coming years, it will become possible to use
NIPT to screen for the same range of conditions that are currently
tested for using karyotyping or microarray technologies at the
follow-up stage, including sex-chromosomal and submicroscopic
abnormalities.89 Commercial providers have already begun expanding
their tests with conditions in this range.90,91
NIPT-based screening for sex-chromosomal aneuploidies
Sex chromosomal aneuploidies (SCA) include full-blown and mosaic
numerical abnormalities leading to syndromes interfering with normal
sexual development. These include Turner syndrome (45, X) and sex-
chromosomal trisomies, such as Klinefelter (XXY) and triple X-syn-
drome (XXX). The impact on general health including psychosocial
development is highly variable. Many individuals with SCA remain
undiagnosed, with fertility problems often provoking the diagnosis.92
Over the past decades, SCA have been detected mainly as additional
ﬁndings of invasive testing. Because of the generally mild phenotype,
those ﬁndings lead to difﬁcult counseling and decision making, and
even more so in case of mosaic SCA.93 Based on EUROCAT data, a
termination rate of 36% for sex-chromosomal trisomies was reported,
as compared to 80–96% for Down syndrome.94,95 Internationally, a
decreasing trend of abortions for SCA is observed, which is attributed
to a generally less bleak prognosis than assumed in the past.94
Incidental prenatal diagnoses of SCA are reported to lead to milder
phenotypes than found in individuals diagnosed on clinical grounds.
Factors associated with decisions to terminate are parental fear of
abnormal development of the child and directive counseling.96
NIPT makes it possible in principle to screen for SCA. Some
commentators regard this as a ‘logical next step’ after the introduction
of the technology in prenatal screening.89 The recent statement of the
Israeli Society of Medical Genetics includes sex-chromosomal
abnormalities in its recommendation that NIPT may be offered to
women at an a priori high risk for fetal chromosomal abnormalities.97
Although commercial companies have already moved to report SCAs
in certain countries, taking this step requires a careful assessment of
the beneﬁts and harms of doing so. Relevant aspects include test
accuracy, counseling challenges, women’s preferences, the interests of
the future child and misuse of information about fetal sex.
The limited available data indicate that NIPT has a lower accuracy
for SCA than for trisomies 21 and 18.18,89,98,99 This is attributed to
several factors including conﬁned placental, placental or true fetal
mosaiscism.42,100 Moreover, a recent study found that in 8.5% of
cases, discordance between NIPT ﬁndings and fetal karyotype could be
directly attributed by an altered (X-chromosome loss) or mosaic
maternal karyotype.100 The authors recommend maternal karyotyping
in case of NIPT results suggesting SCA, in order to improve the
interpretation of such ﬁndings. Thus routine implementation of
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screening for sex chromosome abnormalities could reverse the
reduction in invasive testing seen following the implementation of
NIPT for aneuploidy in the private sector by increasing the false
positive rate through the identiﬁcation of maternal sex chromosome
abnormalities.
Speciﬁc counseling challenges and psychological impacts of NIPT
for SCA have not yet been researched. However, the fact that with
NIPT, SCAs are found at the screening step rather than as an
additional ﬁnding of invasive follow-up testing seems a relevant
difference, as it invites women not only to think about whether they
would want to continue the pregnancy after a conﬁrmed SCA
diagnosis but also whether they would want to take the risk of
invasive testing to rule out the probably more than 50% chance of a
false alarm. The speciﬁcs of different SCAs, for instance the fact that
99% of 45,X fetuses miscarry, and that those who survive often also
have abnormalities that are detected by ultrasound screening,101 will
have to be taken into account.
Little is yet known about women’s preferences about prenatal
screening for SCAs. Recent Chinese studies found that most women
having NIPT for common autosomal aneuploidies also wanted
information about NIPT results for SCA, but reported very different
levels of interest in conﬁrmatory invasive testing.99,102
As most prenatally found SCAs do not lead to pregnancy termination,
a morally relevant question is also what active screening for these
conditions means for the children subsequently born with a (suspected
or conﬁrmed) SCA diagnosis. On the one hand, prenatal detection will
allow early treatment of health and behavioural problems (as well as,
perhaps, timely fertility preservation) and may thus enhance the
child’s quality of life.93 On the other hand, there are concerns about
psychosocial harm (effect on self-esteem, parent-child interaction and
stigmatization) as a consequence of being born with a diagnosis that
otherwise might never have been made in many cases (or only much
later as a result of fertility problems).103 Clearly more research is
needed to clarify this balance.104
Finally, a concern is that screening for SCAs by NIPT will make it
impossible to avoid providing information about fetal sex to women
or couples who might want to use this for aborting female fetuses
(see above). Whether this would in itself amount to a prohibitive
consideration depends on how large the misuse risk would be in the
sociocultural context.
NIPT-based screening for chromosomal microdeletion syndromes
Several commercial companies have started offering expanded NIPT
panels that also test for selected microdeletion syndromes
(eg DiGeorge, Prader Willi/Angelman, Cri-du-chat, Wolf–Hirschhorn)
with a phenotype including developmental delay, intellectual disability,
dysmorphic features and other malformations.90 Concerns have been
raised that this expansion of the screening offer is based on proof of
principle rather than validation studies, and that with the rarity of
most of these microdeletion syndromes, the PPV is expected to be
low.91 Multiple false positives as a result of screening for microdele-
tions will undermine the main achievement of NIPT in the context of
prenatal screening: the signiﬁcant reduction of the invasive testing rate.
Depending on the resolution used for expanded NIPT, more of the
recently identiﬁed smaller microdeletion (and duplication) syndromes
may also be detected. Many of these are associated with generally
milder phenotypes, whereas some may even be present in healthy
individuals.105 With higher resolutions, variants may also be found of
which the clinical signiﬁcance is still unknown. Screening for these
conditions and subsequent follow-up testing (also of the parents) will
lead to information and counseling challenges, as well as burdening
pregnant women or couples with difﬁcult decision making.106
This is not to deny that selected (well characterized and serious)
microdeletion syndromes are candidate conditions for broader NIPT-
screening scenarios that in the coming years may be considered also in
settings where prenatal screening is a public health service. However,
this requires more scientiﬁc evidence (validation studies), as well as a
thorough assessment of the balance of beneﬁts and harms for those to
whom the screening is offered, taking account of the aim of the
screening. In particular an evaluation of the false positive rate is
required as in some studies it has been reported to be as high as 3%.107
In addition, the limits of detection are unknown and small rearrange-
ments may not be detected. Finally, the targeted approach may not be
appropriate as the majority of pathogenic rearrangements arise de novo
and are non-recurring.
Deﬁning the scope of prenatal screening for fetal abnormalities
Given proof of principle regarding the analysis of the entire fetal
genome in maternal plasma,108,109 it is expected to eventually become
technically possible to turn NIPT-based screening into a comprehensive
fetal genome scan, looking beyond chromosomal abnormalities to
Mendelian disorders and genetic risk proﬁles for multifactorial
diseases. For the time being, costs remain prohibitive, but as
sequencing and analysis get cheaper, this will become a realistic
possibility for the future.
Inevitably, this raises the question of what the scope of prenatal
screening for fetal abnormalities should be. Interestingly, the normative
framework does not seem to contain a ready answer. Indeed, one
might argue that by using genomic technologies in order to ﬁnd as
many fetal abnormalities as possible, is very much in line with the
autonomy paradigm, as this would maximally expand the range of
options for reproductive choice. However, there are some problems
with this idea of ‘looking for everything’ that seem to call for a more
cautious expansion of the practice.9,52
Firstly, unlimited choice may paradoxically undermine rather than
serve or enhance reproductive autonomy.110 Identifying traits with low
or variable medical morbidity, as well as variants of uncertain clinical
signiﬁcance, may actually render it more difﬁcult for pregnant women
and their partners to make meaningful reproductive choices.111
Expanding the scope of prenatal screening beyond a limited range
of well-characterized conditions will also make it more difﬁcult to
provide adequate pretest information, help women to make an
informed decision about whether or not to have the test, and to
provide them with meaningful options for indicating which information
they would or would not want to receive.79 As a further complication,
expanding the scope will increase the chance of ﬁndings that may have
implications for the health prospects of the genetic parents themselves,
as well as of their close relatives.
As a possible solution for the pretest information challenge, an
alternative approach to informed consent for multi-disorder screening
has been suggested that would avoid information-overload while still
allowing well-informed decision making. This model of ‘generic’
consent involves presenting pretest information in general categories
or types of outcomes, differentiated in view of their implications for
the future child’s health and well-being.79,112 This would also enable
women or couples to decide about which outcomes they do and do
not want to be informed. However, the practical feasibility of this
model has not yet been empirically tested in the prenatal context, and
ethically, the question remains how ‘informed’ such generic consent
would be, also in the light of the fact that the trade-offs involved will
not be valued in the same way by all pregnant women.68
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Secondly, given that expanded prenatal screening will reveal risk
factors and abnormalities beyond serious childhood disorders, and
that most of these will not lead to the woman asking for an abortion,
the interests of the future child need to be taken into account. His or
her interest in being protected against psychosocial and informational
harm, and related autonomy rights, have not until now had a role in
the ethics of prenatal screening. This will have to change with the
possibility of a much wider range of ﬁndings, including gene-defects
that predispose for serious later onset disorders. According to several
current guidelines, testing children for such conditions is problematic
unless there are effective treatments or opportunities for prevention
that have to be started during childhood.113–115 The concern is that
this will do the child more harm than good, while also preempting his
or her right to choose at a later age between knowing and not-
knowing. Using a term coined by the American philosopher Feinberg,
this has been referred to as a possible violation of the child’s ‘right to
an open future’.116 One need not only think here of serious late-onset
disorders. A possible interest of the child in not-knowing may also be
at stake when prenatal screening targets abnormalities so minor that
most genotypically affected individuals have a normal health
(as discussed above, this is also the case for some sex-chromosomal
abnormalities). Which information would indeed be harmful and to
what extent and what this should mean for the morality of offering
prenatal screening and testing for speciﬁc conditions are matters for
further research and debate.9
In the context of prenatal diagnosis of neurogenetic disorders
(such as Huntington disease), a form of ‘conditional access’ to testing
has been proposed as an ethically acceptable way out of the dilemma
between respecting reproductive autonomy on the one hand and
protecting the interests and autonomy rights of the future child on the
other.117,118 Following recent guidelines, the requesting couple should
be told that ‘if they intend to complete the pregnancy whether the
fetus is a carrier of the gene expansion or not, there is no valid reason
for performing the test’.119 However, this approach seems ill suited to
the different context of broad-scope prenatal screening which is not
for one speciﬁc condition only, nor for conditions that those being
tested can be expected to be already familiar with. This concern is also
relevant in view of the realistic expectation that non-invasive screening
will lead to an increased uptake ‘just for information’. Curiosity on the
part of the future parents needs to be balanced with the risk of
exposing the future child to possibly harmful information.120
Pending further research and debate about the above concerns,
there seems to be good reason for not moving beyond ‘serious
congenital and childhood onset disorders’ when it comes to the scope
of prenatal screening for fetal abnormalities. This can be justiﬁed in
the light of the normative framework as providing women or couples
with meaningful reproductive choices rather than with the
(theoretical) option of receiving all information that genomic
technologies can possibly reveal about the fetus. This is also in line
with ﬁndings of attitudinal research among British and Dutch
pregnant women. Concerns about wider testing included a slippery
slope toward testing for minor abnormalities or cosmetic traits and a
trivialization of abortion.66,121 Dutch women said they wanted the
possibility of testing ‘for severe or fatal disorders that could lead to the
early death of the child or a very low quality of life’.66
When prenatal screening for fetal abnormalities is publicly funded,
considerations of distributive justice point in the same direction. Even
when, with decreasing sequencing costs, it will become possible to
chart the full genome of the fetus in one test, it will still be the case
that a wider range of possible outcomes will require more information
and more complex counseling. Inevitably, this requires deﬁning
‘meaningful reproductive choices’ in a way that can be recognized
by the tax payers whose solidarity is invoked to uphold the service,
rather than leaving this to the private understanding of the pregnant
woman and her partner.
Clearly, this demarcation of the scope of prenatal screening would
require further speciﬁcation. Moreover, practical solutions such as
designing ﬁlters will be needed in order to as much as possible avoid
generating extra information beyond the conditions for which the
screening is offered.
PRENATAL SCREENING FOR DIFFERENT PURPOSES
Historically and ethically, prenatal screening for fetal abnormalities
such as Down syndrome is to be distinguished from prenatal screening
for conditions relevant to a healthy outcome of the pregnancy for
mother and child. The latter practice includes screening for infectious
diseases (such as hepatitis B, syphilis and HIV), rhesus factor and
irregular erythrocyte antibodies. Unlike autonomy-aimed screening for
fetal abnormalities such as Down syndrome, this other form of
prenatal screening is aimed at prevention as a public health aim.
For reasons already indicated (see above), this is an important
distinction, with implications for how prenatal screening is to be
presented and counseled and evaluated. As long as the two forms of
prenatal screening are distinct practices, there need not be a problem
with these different aims, but if they run together, there is a risk of
moral messages getting mixed up.122,123
This is already a concern with the second trimester ultrasound
examination, which is both a form of screening for fetal abnormalities
that may lead to an abortion decision, and an instrument of pregnancy
monitoring in the interest of a healthy outcome for mother and child.
A similar conﬂuence of screening with different purposes emerges
when the biochemical markers used in cFTS as a test for common
autosomal aneuploidies are simultaneously used to also test for
pregnancy complication risks such as pre-eclampsia or intra-uterine
growth retardation.82 As previously indicated, the potential of cFTS to
be used as a dual purpose test in this sense has a role in the debate
about whether or not NIPT should (eventually) replace cFTS as a ﬁrst-
tier screen for fetal abnormalities.61,62
Further possibilities for multipurpose use may arise with NIPT.
Already, NIPT is used for both types of prenatal testing: not just to
screen for common autosomal aneuploidies, but also for determining
the rhesus status of fetuses of RhD negative women.124 These uses of
NIPT were developed as separate tests to be conducted in different
periods of the pregnancy, but they can in principle be combined into
one test in early pregnancy. There are conﬂicting reports in the
literature about the possibility of using altered levels of cell-free fetal
DNA as a marker for placental complications such as pre-eclampsia,
growth retardation and preterm birth.33,125 If indeed possible, this
might be a further instance of dual purpose NIPT. Moreover, it has
been suggested that in the future, NIPT might be used to detect gene-
expression patterns that would predict pregnancy complications and
other problems with fetal development.70
What should be avoided here, with regard to these different types of
prenatal screening, is confusing women and couples about what they
are offered testing for, and what they can accept or decline, and on the
basis of what considerations to decide about this. Whereas counseling
for autonomy-aimed screening should be neutral and non-directive,
there is no ethical problem with recommending prevention-aimed
screening for maternal/fetal risk factors as something to be seriously
considered by all pregnant women. As it will be difﬁcult to keep these
messages apart, it is ethically preferable to physically or temporarily
keep autonomy- and prevention-aimed screening separated as much
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as possible.123 When this is impossible in practice (as also in the case
of prenatal ultrasound), counselors should be aware of the need to
avoid confusion by conceptually separating the two kinds of screening.
A recent review has sketched a future scenario in which broad-scope
NIPT (using different types of ‘omics’-information) will allow prenatal
screening to turn into ‘fetal personalized medicine’.70 If this means
that disorders that are now untreatable become treatable in utero,
prenatal screening for those disorders will give the woman or the
couple more options than only the choice between completion and
termination of pregnancy, including treatments that may beneﬁt the
health prospects of the future child. The question arises what this
should mean for the ethical framework. To what extent does the
option of fetal therapy introduce considerations of parental and
professional responsibility that require reconsidering the autonomy
framework? A proactive ethical analysis of the implications of this
development will be needed.52
PRENATAL SCREENING AS A PUBLIC HEALTH
RESPONSIBILITY
In many countries, prenatal screening has in the past decades been
offered to pregnant women in the form of national or regional
population screening programmes. These programmes are run as
public health services or are at least quality controlled by public health
authorities. The idea behind these programmes and their funding
from public money is that reproductive health is a collective
responsibility and that this includes the ability to make meaningful
reproductive choices related to the possibility of having a child with a
serious disease or handicap.45
Whereas in the past, new screening technologies (such as cFTS
replacing the second trimester triple test) have been readily introduced
in these programmes, the introduction of NIPT into clinical practice
has until now been largely left to commercial laboratories offering
their version of the test through individual practitioners and practices,
without governments or public health authorities assuming an active
role in this process. Given the importance of offering NIPT in a setting
in which all relevant aspects (including information and counseling)
are quality controlled, it is time that these actors take a more active
role. The recent UK initiative to study how NIPT can optimally be
introduced within available budget constraints is a step in this
direction.62 Another example is the TRIDENT study (Trial by Dutch
laboratories for Evaluation of Non-Invasive Prenatal Testing) of the
Dutch National NIPT consortium, which consists of a comprehensive
evaluation of the stepwise introduction of NIPT in prenatal screening
for common aneuploidies in the Netherlands, for which the Ministry
of Health has granted a license under the Dutch Population Screening
Act.126
The notion that prenatal screening should be regarded a public
health responsibility may, but does not necessarily entail that all costs
are paid from public money without asking for any (co-)payment
from those being tested. It is important to note that these are separate
(though connected) issues. In light of the aim of providing options for
reproductive choice, it might be argued that asking women to pay for
prenatal screening increases the awareness that there is truly a choice
to be made.127 On the other hand, depending on the height of the
ﬁnancial barrier, this may limit access to prenatal screening to those
who are better off, which raises an issue of justice.
Societal spending on prenatal screening is commonly justiﬁed by
appeal to the importance of the reproductive autonomy interests of
intended parents.45 A more contentious argument is that prenatal
screening leads to long-term societal savings by avoiding the high costs
of lifetime care for people with conditions such as Down syndrome.
There is nothing inherently problematic about this ‘savings argument’,
as long as it is not turned into an alternative account of the aim of
prenatal screening.128 Although higher public spending on NIPT-
based prenatal screening may well be outweighed by these long-term
savings,129,130 it is not obvious how the necessary calculations should
be done, even apart from the reality of short-term budgetary
constraints.131 In the light of those constraints, implementing NIPT
as a ﬁrst-tier test in a fully funded prenatal screening programme may
only become possible if the cost per unit can be brought down
considerably.130–132 In fact, the costs of NIPT are decreasing and
companies have announced a low-cost NIPT by the end of 2014. But
even if, at least for the time being, prenatal screening with NIPT as a
ﬁrst-tier test will require private (co-)payment, much will be gained if
such screening is offered in a setting guaranteeing quality control of all
relevant aspects, including information, counseling and follow-up.
This requires an active engagement of governments and public health
authorities.
Determining the parameters of what should be offered as part of an
ethically robust prenatal screening programme in the public realm is
important as it will set a clear standard for the use of NIPT. Our view
is that any programme that is established should be in accordance with
the aforementioned ethical principles. An active and coordinating role
of public health authorities is also needed to address the challenges
arising with emerging possibilities of combining autonomy- and
prevention-aimed forms of prenatal screening, including prenatal
screening opening up possibilities for prenatal therapy and to set up
a governance structure for responsible innovation in this ﬁeld.133
NIPT AS A COMMERCIAL DTC-TEST
Whereas cFTS screening (because of the ultrasound component)
requires direct contact with a health professional, NIPT makes it
possible in theory to offer prenatal testing for fetal abnormalities as a
direct-to-consumer test.134 Ethically, this would be a problematic
development. In order to maintain minimum quality standards,
prenatal testing for fetal abnormalities should always be offered
through health professionals with the expertise and training to provide
the necessary pre-and post-test information and counseling. This is
also how NIPT is currently made available by the companies selling
the test. However, direct advertising to the target group of pregnant
women who then only need to ask for the right product, may serve to
diminish the role of the professional as an independent advisor and is
therefore also an issue of concern.
Currently, NIPT is available through the internet as a commercial
DTC-test speciﬁcally for fetal sex determination and paternity testing.
In light of the above discussion of NIPT results being potentially used
to abort healthy female fetuses just because of being of the ‘wrong’ sex,
it is clear that DTC-tests for early fetal sex determination should be
regarded with concern, given that those who only want to know what
color to paint the baby room will have ample opportunity to learn
about the sex of the fetus later in pregnancy. Although paternity
testing may lead to abortion of healthy fetuses as well, women may
have legitimate reasons for wanting to know the identity of the father
of the child they are carrying.10 Paternity testing, however, also raises
issues of consent and privacy.
RECOMMENDATIONS
1. NIPT offers improved accuracy when testing for common
autosomal aneuploidies compared with existing tests such as
cFTS. However, a positive NIPT result should not be regarded as a
ﬁnal diagnosis: false positives occur for a variety of reasons
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(including that the DNA sequenced is both maternal and fetal in
origin, and that the fetal fraction derives from the placenta as well
as the developing fetus). Thus women should be advised to have a
positive result conﬁrmed through diagnostic testing, preferably by
amniocentesis, if they are considering a possible termination of
pregnancy.
2. The better test performance, including lower invasive testing rate
of NIPT-based screening should not lead to lower standards for
pretest information and counseling. This is especially important in
the light of the aim of providing pregnant women with mean-
ingful options for reproductive choice. There should be speciﬁc
attention paid to the information needs of women from other
linguistic and cultural backgrounds or who are less health literate.
3. If NIPT is offered for a speciﬁc set of conditions (eg trisomies 21,
18 and 13), it may not be reasonably possible to avoid additional
ﬁndings, such as other chromosomal anomalies or large scale
insertions or deletions. As part of pretest information, women and
couples should be made aware of the possibility of such additional
ﬁndings and the range of their implications. There should be a
clear policy for dealing with such ﬁndings, as much as possible
also taking account of pregnant women’s wishes with regard to
receiving or not receiving speciﬁc information.
4. Expanding NIPT-based prenatal screening to also report on sex-
chromosomal abnormalities and microdeletions not only raises
ethical concerns related to information and counseling challenges
but also risks reversing the important reduction in invasive testing
achieved with implementation of NIPT for aneuploidy, and is
therefore currently not recommended.
5. Emerging opportunities for combining prenatal screening for fetal
abnormalities with screening aimed at prevention may undermine
adequate counseling by sending mixed messages. The objective of
any prenatal screening activity should be made explicit and, as far
as possible, forms of prenatal screening with different aims should
be presented separately. If not physically possible, this separation
should at least be made conceptually when providing the relevant
information.
6. In countries where prenatal screening for fetal abnormalities is
offered as a public health programme, governments and public
health authorities should adopt an active role to ensure the
responsible introduction of NIPT as a second or ﬁrst-tier screen-
ing test for Down syndrome and other common autosomal
aneuploidies. This entails ensuring quality control also extending
to the non-laboratory aspects of NIPT-based prenatal screening
(information, counseling), education of professionals, systematic
evaluation of all aspects of the screening programme, as well as
promoting equity of access for all pregnant women within the
conﬁnes of the available budget, and setting up a governance
structure for responsible further innovation in prenatal
screening.
7. Different scenarios for NIPT-based screening for common auto-
somal aneuploidies are possible, including NIPT as an alternative
ﬁrst-tier option. The inevitable trade-offs underlying those sce-
narios should not just be regarded as a matter of screening
technology and health economics; the question is also how these
trade-offs enable or impede meaningful reproductive choices and
how they affect both the balance of beneﬁts and burdens for
pregnant women and their partners, and the screening goals and
values acceptable to society.
8. In order to adequately evaluate prenatal screening practices, there
is a need to further develop and validate measures of informed
choice as well as interventions aimed at enabling informed
choices. The transition to NIPT-based prenatal screening presents
an opportunity to ﬁll this gap in knowledge.
9. In the light of sequencing technologies becoming better and
cheaper, there is an acute need for a proactive professional and
societal debate about what the future scope of prenatal screening
for fetal abnormalities should be. As argued in this document,
there are strong ethical reasons for not expanding the scope of
prenatal screening beyond serious congenital and childhood
disorders.
10. The scenario in which prenatal screening would open up
possibilities for fetal therapy in addition to autonomous repro-
ductive choice raises fundamental questions about the relation
between reproductive autonomy and parental responsibility that
require an in depth proactive ethical analysis.
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